These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805 [TBL] [Abstract][Full Text] [Related]
3. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival. Hyldgaard C Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544 [TBL] [Abstract][Full Text] [Related]
4. Clusters of comorbidities in fibrotic hypersensitivity pneumonitis. Prior TS; Wälscher J; Gross B; Bendstrup E; Kreuter M Respir Res; 2022 Dec; 23(1):368. PubMed ID: 36539821 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg). Krauss E; El-Guelai M; Pons-Kuehnemann J; Dartsch RC; Tello S; Korfei M; Mahavadi P; Breithecker A; Fink L; Stoehr M; Majeed RW; Seeger W; Crestani B; Guenther A J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32756496 [TBL] [Abstract][Full Text] [Related]
6. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169 [TBL] [Abstract][Full Text] [Related]
7. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Hyldgaard C; Hilberg O; Pedersen AB; Ulrichsen SP; Løkke A; Bendstrup E; Ellingsen T Ann Rheum Dis; 2017 Oct; 76(10):1700-1706. PubMed ID: 28611082 [TBL] [Abstract][Full Text] [Related]
8. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis. Schwarzkopf L; Witt S; Waelscher J; Polke M; Kreuter M Respir Res; 2018 Apr; 19(1):73. PubMed ID: 29695236 [TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognosis of unclassifiable interstitial lung disease. Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877 [TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. Fisher JH; Kolb M; Algamdi M; Morisset J; Johannson KA; Shapera S; Wilcox P; To T; Sadatsafavi M; Manganas H; Khalil N; Hambly N; Halayko AJ; Gershon AS; Fell CD; Cox G; Ryerson CJ BMC Pulm Med; 2019 Nov; 19(1):223. PubMed ID: 31771541 [TBL] [Abstract][Full Text] [Related]
11. Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. Frank AL; Kreuter M; Schwarzkopf L Respir Med; 2019 Jun; 152():25-31. PubMed ID: 31128606 [TBL] [Abstract][Full Text] [Related]
12. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a Molina-Molina M; Kreuter M; Cottin V; Corte TJ; Gilberg F; Kirchgaessler KU; Axmann J; Maher TM Front Med (Lausanne); 2022; 9():897102. PubMed ID: 35783648 [TBL] [Abstract][Full Text] [Related]
14. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Zamora-Legoff JA; Krause ML; Crowson CS; Ryu JH; Matteson EL Rheumatology (Oxford); 2017 Mar; 56(3):344-350. PubMed ID: 27940586 [TBL] [Abstract][Full Text] [Related]
15. Co-morbidity and mortality among patients with interstitial lung diseases: A population-based study. Hilberg O; Bendstrup E; Løkke A; Ibsen R; Fløe A; Hyldgaard C Respirology; 2018 Jun; 23(6):606-612. PubMed ID: 29251396 [TBL] [Abstract][Full Text] [Related]
16. Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices. Jacob J; Bartholmai BJ; Rajagopalan S; Egashira R; Brun AL; Kokosi M; Nair A; Walsh SLF; Karwoski R; Nicholson AG; Hansell DM; Wells AU Respir Med; 2017 Sep; 130():43-51. PubMed ID: 29206632 [TBL] [Abstract][Full Text] [Related]
18. Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers. Cinetto F; Scarpa R; Carrabba M; Firinu D; Lougaris V; Buso H; Garzi G; Gianese S; Soccodato V; Punziano A; Lagnese G; Tessarin G; Costanzo G; Landini N; Vio S; Bondioni MP; Consonni D; Marasco C; Del Giacco S; Rattazzi M; Vacca A; Plebani A; Fabio G; Spadaro G; Agostini C; Quinti I; Milito C Front Immunol; 2021; 12():627423. PubMed ID: 33777011 [No Abstract] [Full Text] [Related]
19. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Chartrand S; Lee JS; Swigris JJ; Stanchev L; Fischer A Lung; 2019 Dec; 197(6):709-713. PubMed ID: 31583453 [TBL] [Abstract][Full Text] [Related]